ArticleHuman genetics2026
A homozygous synonymous variant in SMG5, encoding a nonsense-mediated mRNA decay factor, causes developmental delay with growth retardation and relative macrocephaly.
Article in Human genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nonsense-mediated mRNA decay and associated splicing patterns in neurodevelopmental disorders.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The nonsense-mediated mRNA decay (NMD) pathway is a translation-dependent mechanism that maintains cellular RNA homeostasis by eliminating mRNAs containing a premature termination codon (PTC). NMD also targets ~ 15% of all physiological coding and non-coding spliced transcripts, thereby playing a significant role in shaping the cellular transcriptome. SMG5 is one of several NMD effector proteins required for the cleavage of mRNAs. In a female patient with craniofacial dysmorphism, developmental delay, severe growth retardation, and relative macrocephaly, we identified the homozygous synonymous variant c.2967G > A; p.Gln989 = in SMG5, affecting the last base of the penultimate exon. In patient fibroblasts, most of the SMG5 pre-mRNAs were aberrantly spliced, while a small proportion of canonically spliced SMG5 transcripts was found. Levels of SMG5 were reduced to ~ 25%. We identified a significant increase in the total protein amount and the size of the cell, Golgi apparatus, and nucleus in patient-derived fibroblasts. Cell proliferation was compromised, and the cell cycle was delayed. Patient fibroblasts showed global transcriptional dysregulation, with genes involved in nucleosome assembly and organization being upregulated and downregulated genes associated with differentiation, development, and morphogenesis. We found a global upregulation of NMD-sensitive transcripts, including a significant and experimentally validated increase in the relative abundance of naturally occurring PTC-containing transcripts of the splicing factor genes SRSF2, SRSF4, SRSF6, and SF3B3 in the patient’s fibroblasts. Together, our findings indicate that the homozygous synonymous SMG5 variant c.2967G > A acts as a hypomorphic allele, associated with mild inhibition of the NMD pathway and underlying the patient’s phenotype.
Indexed as
Identifiers
41758221What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.